Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.

This study represents the first of ten prospective clinical trials in oncology patients, which fails to show a benefit for the addition of intravenous iron to erythropoiesis-stimulating agents in improving hemoglobin responses. The patient population was the largest reported to date (502), the trial was well done, and prospective, multicenter with a placebo control. No […]